Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (NCT03767348)
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
🩺 Plain-English Summary (8th-Grade Level)
The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients with Stage IIIb-IV unresectable melanoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, non-melanoma skin cancer (NMSC), and non-small cell lung cancer (NSCLC).
Who can join: Review the eligibility criteria below.
Location: University of Birmingham Alabama — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (51 Sites)
Showing the first 25 of 51 sites.
- University of Birmingham Alabama — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic — Phoenix, Arizona
- Carti Cancer Center — Little Rock, Arkansas
- UC San Diego — La Jolla, California
- University of Southern California — Los Angeles, California
- UCLA — Los Angeles, California
- University of California, Irvine — Orange, California
- University of California- San Francisco — San Francisco, California
- Sylvester Comprehensive Cancer Center- University of Miami — Miami, Florida
- University of Iowa-Cancer Center Research — Iowa City, Iowa
- James Graham Brown Cancer Center- University of Louisville — Louisville, Kentucky
- Mayo Clinic — Rochester, Minnesota
- New York University Clinical Cancer Center — New York, New York
- Weill Cornell Medical College — New York, New York
- University of Rochester Medical Center — Rochester, New York
- Duke Cancer Center — Durham, North Carolina
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Providence Portland Medical Center — Portland, Oregon
- MUSC Health — Charleston, South Carolina
- West Cancer Center — Germantown, Tennessee
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Eccles Outpatient Care Center- Oncology Clinical Trials — Murray, Utah
- Intermountain Cancer Center- Saint George Cancer Center — St. George, Utah
- Seattle Cancer Care Alliance- University of Washington — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer (NSCLC)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
Explore by condition: All Non-Small Cell Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.